Papillary thyroid cancer (PTC) is the most common type of malignant thyroid tumor, accounting for up to 80% of all cases of cancer in this localization. PTC develops from the follicular cells of the thyroid gland and is characterized by slow growth, but can metastasize to the lymph nodes of the neck, which requires careful monitoring and timely treatment. Despite the relatively favorable prognosis in most cases, the possibility of relapse and metastasis should not be underestimated, which makes early diagnosis and adequate treatment critically important.
History of the disease and interesting historical facts
The history of papillary thyroid cancer includes many interesting events related to its discovery and study. The first mentions of thyroid diseases date back to ancient sources, where signs of thyroid enlargement were already described. In the 19th century, with the development of pathological anatomy, doctors began to study malignant neoplasms more actively, and it was then that the papillary form of cancer was identified. In the 1930s, thanks to the efforts of scientists such as Ota, a separate category was identified for papillary thyroid cancer, which marked the beginning of its more detailed study. In the following years, diagnostic and treatment methods were developed that can significantly increase patient survival, but the tasks of studying genetic and molecular mechanisms remain relevant today.
Epidemiology
Papillary thyroid cancer can occur in different populations and regions, and its prevalence has clear geographic, gender, and age differences. Studies show that the highest incidence is observed in countries with high levels of iodine in the diet, while in regions with a deficiency of this element, a lower incidence is noted. Statistics show that PTC is more common in women, with the ratio of women to men being approximately 3:1. The peak incidence occurs in the age groups of 30-50 years, but it can also occur at a younger age. According to the World Health Organization, an increase in the incidence of PTC has been observed recently, which may be due to both improved diagnostic skills and the impact of environmental factors.
Genetic predisposition to this disease
There is a significant genetic predisposition to papillary thyroid cancer and in this context it is important to highlight the key genetic factors and mutations that contribute to its development. Studies show that mutations in the RET and BRAF genes play an important role in the pathogenesis of PTC. The RET gene is usually associated with hereditary syndromes such as multiple endocrine neoplasia type II, while mutations in the BRAF gene are observed in a significant proportion of spontaneous cases of PTC. In addition to the above genes, attention is also drawn to the involvement of the TP53 and RAS genes, which can modify the risk of developing this carcinoma. Modern molecular studies continue to identify new genetic changes that can affect the tumor process.
Risk factors for the development of this disease
Risk factors for developing papillary thyroid cancer can be divided into several categories:
- Physical factors:
- Childhood radiation to the head and neck, including cancer treatment.
- Increased levels of radiation in the environment.
- Chemical factors:
- Exposure to chemicals such as pesticides and solvents.
- Environmental pollution with heavy metals.
- Other factors:
- Hereditary predisposition to thyroid cancer.
- Thyroid pathologies such as Hashimoto's thyroiditis.
A clear understanding of risk factors can facilitate early diagnosis and prevention of the disease.
Diagnosis of this disease
Diagnosis of papillary thyroid cancer involves various methods that allow the disease to be detected at an early stage. The main symptoms may be non-specific and include painless enlargement of the thyroid gland, difficulty swallowing or breathing. Laboratory tests, such as blood tests for thyroid hormones and thyroglobulin, are important, as they can indicate the functional state of the thyroid gland. Radiological examinations, including thyroid ultrasound, are necessary to visualize nodular formations. In such cases, fine-needle biopsy may be required to obtain cytology specimens and confirm the diagnosis. Differential diagnosis should be made with other types of thyroid tumors, as well as with benign diseases, such as nodular goiter.
Treatment
Treatment of papillary thyroid cancer depends on the stage of the disease and the individual characteristics of the patient. General treatment includes surgery, which is a key element of therapy, allowing the tumor and lymph nodes to be removed. Depending on the extent of the process, a thyroidectomy or hemithyroidectomy may be performed. Pharmacological treatment may include the administration of radioactive iodine after surgery to ablate residual thyroid tissue, as well as to treat metastases. In some cases, radiation therapy may be required, especially in the presence of relapses. There are also targeted therapy methods aimed at blocking molecular targets.
List of medications used to treat this disease
- Levothyroxine sodium – to replace thyroid hormones after surgery.
- Radioactive iodine (I-131) – for ablation of residual tissue and metastases.
- Targeted drugs such as lentinocan and sertinib for metastatic cases.
Disease monitoring
Monitoring of papillary thyroid cancer is important to assess the effectiveness of treatment and to detect possible recurrences in a timely manner. Control stages usually include regular ultrasound examinations, blood tests for thyroglobulin levels, and observation of clinical symptoms. The prognosis is favorable in most cases, but the necessary measures to prevent recurrence should be strictly followed according to research data. Complications may include metastasis to the lungs and bones, as well as thyroid dysfunction after surgical treatment.
Age-related features of the disease
Age-related features of papillary thyroid cancer can vary significantly. In children and adolescents, this disease often proceeds more aggressively than in older patients, where, as a rule, a slower progression is observed. In women, the disease is more often diagnosed in reproductive age, while in men, the probability of the tumor process increases with age. It is important to take into account the age of more careful observation and selection of appropriate therapy.
Questions and Answers
- What are the main symptoms of papillary thyroid cancer?
The main symptoms include an enlarged thyroid gland, nodules, and difficulty swallowing or breathing. - How is papillary thyroid cancer diagnosed?
Diagnosis is based on ultrasound, biopsy, thyroglobulin tests and clinical examination. - What is the treatment for papillary thyroid cancer?
Treatment includes surgery, radioactive iodine and, in some cases, targeted therapy. - What is the prognosis for patients with papillary thyroid cancer?
The prognosis is favorable in most cases, but constant monitoring for relapse is necessary. - Is there a genetic predisposition to this disease?
Yes, mutations in the RET and BRAF genes can increase the risk of developing papillary thyroid cancer.
